215 related articles for article (PubMed ID: 24146233)
21. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
[TBL] [Abstract][Full Text] [Related]
22. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
23. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.
Khoury H; Kashyap A; Adkins DR; Brown RA; Miller G; Vij R; Westervelt P; Trinkaus K; Goodnough LT; Hayashi RJ; Parker P; Forman SJ; DiPersio JF
Bone Marrow Transplant; 2001 May; 27(10):1059-64. PubMed ID: 11438821
[TBL] [Abstract][Full Text] [Related]
24. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.
Calkoen FG; Jol-van der Zijde CM; Mearin ML; Schweizer JJ; Jansen-Hoogendijk AM; Roelofs H; van Halteren AG; Egeler RM; van Tol MJ; Ball LM
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1590-9. PubMed ID: 23994245
[TBL] [Abstract][Full Text] [Related]
25. Dismal response to high-dose methylprednisolone after failure to respond to standard dose in patients with acute GVHD.
Schechter T; Macartney C; Finkelstein Y; Gassas A; Husain M; Doyle J; Dupuis LL
Bone Marrow Transplant; 2010 Dec; 45(12):1749-53. PubMed ID: 20208573
[TBL] [Abstract][Full Text] [Related]
26. Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility.
Wang Y; Xu LP; Liu KY; Liu DH; Wang J; Chen H; Chen YH; Han W; Huang XJ
Bone Marrow Transplant; 2011 Jun; 46(6):892-8. PubMed ID: 20711243
[TBL] [Abstract][Full Text] [Related]
27. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease.
Giaccone L; Martin P; Carpenter P; Moravec C; Hooper H; Funke VA; Storb R; Flowers ME
Bone Marrow Transplant; 2005 Aug; 36(4):337-41. PubMed ID: 15968296
[TBL] [Abstract][Full Text] [Related]
28. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
[TBL] [Abstract][Full Text] [Related]
29. Cord blood transplantation from unrelated donors for children with acute lymphoblastic leukemia in Japan: the impact of methotrexate on clinical outcomes.
Kato K; Yoshimi A; Ito E; Oki K; Hara J; Nagatoshi Y; Kikuchi A; Kobayashi R; Nagamura-Inoue T; Kai S; Azuma H; Takanashi M; Isoyama K; Kato S;
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1814-21. PubMed ID: 21664471
[TBL] [Abstract][Full Text] [Related]
30. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
32. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
Koga Y; Nagatoshi Y; Kawano Y; Okamura J
Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
[TBL] [Abstract][Full Text] [Related]
33. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
[TBL] [Abstract][Full Text] [Related]
34. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.
Ball LM; Bernardo ME; Roelofs H; van Tol MJ; Contoli B; Zwaginga JJ; Avanzini MA; Conforti A; Bertaina A; Giorgiani G; Jol-van der Zijde CM; Zecca M; Le Blanc K; Frassoni F; Egeler RM; Fibbe WE; Lankester AC; Locatelli F
Br J Haematol; 2013 Nov; 163(4):501-9. PubMed ID: 23992039
[TBL] [Abstract][Full Text] [Related]
35. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
Kim SS
Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
[TBL] [Abstract][Full Text] [Related]
36. Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
Martínez C; Solano C; Ferrá C; Sampol A; Valcárcel D; Pérez-Simón JA;
Biol Blood Marrow Transplant; 2009 May; 15(5):639-42. PubMed ID: 19361757
[TBL] [Abstract][Full Text] [Related]
37. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation.
de Lavallade H; Mohty M; Faucher C; Fürst S; El-Cheikh J; Blaise D
Haematologica; 2006 Oct; 91(10):1438-40. PubMed ID: 16963392
[TBL] [Abstract][Full Text] [Related]
38. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
[TBL] [Abstract][Full Text] [Related]
39. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR
Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]